Opdivo (nivolumab)

December 3, 2018

AB122 Controls Disease in Half of Solid Tumor Patients in Phase 1 Trial

News

A potential antibody treatment called AB122 enabled tumor reduction and stable disease in half of patients with ovarian cancer and other types of advanced tumors, according to early results of an ... Read more

November 2, 2018

Compugen, Bristol-Myers Squibb Collaborating to Test COM701, Opdivo Combo for Ovarian, Other Cancers

News

Compugen has entered into a clinical trial collaboration with Bristol-Myers Squibb (BMS) to evaluate the safety and preliminary effectiveness of its investigational immunotherapy COM701 in combination with BMS’ Opdivo (nivolumab), in a ... Read more

August 14, 2017

BMS and Clovis Collaborate to Test Opdivo, Rubraca Combo Therapy in Ovarian, Other Cancer Types

News

A new clinical collaboration has been established between Bristol-Myers Squibb (BMS) and Clovis Oncology to evaluate the performance of Opdivo (nivolumab) in combination with Rubraca (rucaparib) in a Phase 3 trial for advanced ovarian cancer. ... Read more

May 10, 2017May 10, 2017

First Patient Enrolled in Phase 1/2 Trial for Recurrent Ovarian Cancer

News

The first patient has been dosed in a Phase 1/2 trial assessing OncoQuest‘s anti-CA125 antibody oregovomab in combination with Opdivo (nivolumab) in women with recurrent ovarian cancer. The ORION-01 trial (NCT03100006), ... Read more